What exactly did Piper Sandler do in the March 04, 2026 ARCT analyst rating update

Piper Sandler maintained an **Overweight** rating on ARCT on March 04, 2026. The firm left its rating unchanged while issuing sector commentary and a related note that lowered views on another name, creating mixed near-term sentiment

Does the maintained Overweight change the ARCT price target landscape

No single maintained rating resets the full target range. Citigroup published a **$8.00** target on March 04, 2026, and 26 firms reported on ARCT in the past year, so investors should compare multiple price targets before acting

How should investors use the ARCT analyst rating when deciding to buy or sell

Treat the maintained Overweight as continued conviction from Piper Sandler. Combine it with clinical timelines, cash runway, and consensus targets. Use the rating as one input, not a sole decision factor

Analyst Ratings

Piper Sandler Maintains Overweight on Arcturus Therapeutics (ARCT) March 2026

ByHuzaifa Zahoor March 5, 2026March 5, 2026

Piper Sandler on March 04, 2026 maintained Overweight on Arcturus Therapeutics Holdings Inc. (ARCT). The ARCT analyst rating move kept a positive stance even as Piper Sandler noted a lower firm-level price view in a broader biotech reset. This action followed the firm’s note titled ‘2026 will be a stock-moving year for ArthroCare (ARTC)’, which referenced sector dynamics that also affect small-cap RNA therapeutics. Investors should view this maintained Overweight as continuity in conviction, not a fresh upgrade or downgrade